Champions Non Current Liabilities Total vs Other Liab Analysis
CSBR Stock | USD 4.31 0.02 0.46% |
Champions Oncology financial indicator trend analysis is way more than just evaluating Champions Oncology prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Champions Oncology is a good investment. Please check the relationship between Champions Oncology Non Current Liabilities Total and its Other Liab accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Champions Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.
Non Current Liabilities Total vs Other Liab
Non Current Liabilities Total vs Other Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Champions Oncology Non Current Liabilities Total account and Other Liab. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Champions Oncology's Non Current Liabilities Total and Other Liab is -0.08. Overlapping area represents the amount of variation of Non Current Liabilities Total that can explain the historical movement of Other Liab in the same time period over historical financial statements of Champions Oncology, assuming nothing else is changed. The correlation between historical values of Champions Oncology's Non Current Liabilities Total and Other Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Liabilities Total of Champions Oncology are associated (or correlated) with its Other Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Liab has no effect on the direction of Non Current Liabilities Total i.e., Champions Oncology's Non Current Liabilities Total and Other Liab go up and down completely randomly.
Correlation Coefficient | -0.08 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Non Current Liabilities Total
Other Liab
Most indicators from Champions Oncology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Champions Oncology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Champions Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.At this time, Champions Oncology's Selling General Administrative is relatively stable compared to the past year. As of 11/29/2024, Sales General And Administrative To Revenue is likely to grow to 0.42, though Tax Provision is likely to grow to (30.4 K).
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 25.5M | 24.3M | 20.8M | 21.8M | Total Revenue | 49.1M | 53.9M | 50.2M | 52.7M |
Champions Oncology fundamental ratios Correlations
Click cells to compare fundamentals
Champions Oncology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Champions Oncology fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 20.8M | 27.6M | 35.4M | 34.3M | 26.1M | 27.4M | |
Short Long Term Debt Total | 3.8M | 9.6M | 9.5M | 8.6M | 7.4M | 7.8M | |
Other Current Liab | 2.5M | 2.2M | 1.4M | 1.2M | 973K | 739.7K | |
Total Current Liabilities | 12.1M | 11.2M | 17.5M | 21.7M | 21.5M | 22.6M | |
Total Stockholder Equity | 5.3M | 7.4M | 9.1M | 4.6M | (1.9M) | (1.8M) | |
Property Plant And Equipment Net | 6.8M | 14.6M | 15.4M | 14.5M | 12.0M | 12.6M | |
Net Debt | (4.5M) | 4.9M | 459K | (1.5M) | 4.8M | 5.1M | |
Retained Earnings | (72.7M) | (72.5M) | (72.0M) | (77.3M) | (84.6M) | (80.4M) | |
Accounts Payable | 3.1M | 1.9M | 2.9M | 5.3M | 5.8M | 6.1M | |
Cash | 8.3M | 4.7M | 9.0M | 10.1M | 2.6M | 3.7M | |
Non Current Assets Total | 7.3M | 15.0M | 15.7M | 14.9M | 12.5M | 13.1M | |
Cash And Short Term Investments | 8.3M | 4.7M | 9.0M | 10.1M | 2.6M | 3.7M | |
Net Receivables | 4.8M | 7.0M | 9.5M | 8.0M | 9.5M | 10.0M | |
Common Stock Shares Outstanding | 11.8M | 14.6M | 14.2M | 13.5M | 13.5M | 14.2M | |
Liabilities And Stockholders Equity | 20.8M | 27.6M | 35.4M | 34.3M | 26.1M | 27.4M | |
Non Current Liabilities Total | 3.3M | 9.0M | 8.8M | 7.9M | 6.5M | 6.8M | |
Other Current Assets | 385K | 957K | 2.3M | 1.3M | 1.5M | 1.6M | |
Other Stockholder Equity | 78.0M | 79.9M | 81.1M | 81.9M | 82.7M | 86.8M | |
Total Liab | 15.4M | 20.2M | 26.3M | 29.7M | 28.0M | 29.4M | |
Property Plant And Equipment Gross | 6.8M | 14.6M | 15.4M | 14.5M | 22.4M | 23.5M | |
Total Current Assets | 13.5M | 12.6M | 19.7M | 19.5M | 13.6M | 14.3M | |
Other Liab | 178K | 181K | 391K | 551K | 633.7K | 500.9K | |
Short Term Debt | 628K | 818K | 2.1M | 2.4M | 2.7M | 2.8M | |
Property Plant Equipment | 6.8M | 14.6M | 15.4M | 14.5M | 16.7M | 17.5M | |
Current Deferred Revenue | 5.8M | 6.3M | 11.1M | 12.8M | 12.1M | 12.7M | |
Retained Earnings Total Equity | (72.7M) | (72.5M) | (72.0M) | (77.3M) | (69.6M) | (73.1M) | |
Net Tangible Assets | 5.0M | 7.1M | 8.8M | 4.3M | 4.9M | 3.9M | |
Capital Surpluse | 78.0M | 79.9M | 81.1M | 82.0M | 94.3M | 77.6M |
Pair Trading with Champions Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Champions Stock
0.49 | VERV | Verve Therapeutics | PairCorr |
0.46 | DRUG | Bright Minds Biosciences | PairCorr |
0.36 | EQ | Equillium | PairCorr |
0.35 | VANI | Vivani Medical | PairCorr |
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.